P. Stephens

P. Stephens, J. Ross, M. Rosenzweig, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

P. Stephens, J. Ross, S. Ou, 2015, Lung cancer.

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Krishna R. Kalari, James X. Sun, K. Kalari, 2015, Journal of the National Cancer Institute.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy

P. Stephens, J. Ross, J. Sosman, 2018, Pigment cell & melanoma research.

Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.

P. Stephens, S. Ou, Siraj M. Ali, 2016, JAMA oncology.

BRAF and RAS mutations in human lung cancer and melanoma.

Richard Wooster, Helen Davies, Michael R Stratton, 2002, Cancer research.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

James X. Sun, P. Stephens, J. Hechtman, 2017, Journal of the National Cancer Institute.

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

S. Armstrong, P. Stephens, R. Yelensky, 2014, Proceedings of the National Academy of Sciences.

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.

M. Stratton, P. Futreal, R. Wooster, 2005, Blood.

M. Stratton, P. Futreal, R. Wooster, 2002, Cancer research.

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling

P. Stephens, S. Ou, B. Halmos, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing

P. Stephens, R. Yelensky, S. Ou, 2016, Clinical Cancer Research.

Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study

P. Stephens, V. Miller, D. Khaira, 2016, Breast Cancer Research and Treatment.

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

P. Stephens, D. Lipson, S. Ou, 2018, The oncologist.

Identification of NTRK fusions in pediatric mesenchymal tumors

P. Stephens, K. Badizadegan, M. Rosenzweig, 2017, Pediatric blood & cancer.

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

P. Stephens, W. Pao, J. Sosman, 2013, Clinical Cancer Research.

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

Tracy T Batchelor, Richard Lugg, Andrew Menzies, 2006, Cancer research.

A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms

P. Stephens, O. Basturk, S. Middha, 2018, Modern Pathology.

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

David M. Jones, P. Stephens, G. Frampton, 2017, The oncologist.

STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion

P. Stephens, V. Miller, Siraj M. Ali, 2015, Journal of Hematology & Oncology.

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.

P. Stephens, D. Lipson, V. Miller, 2014, Cancer discovery.

Tumors Harbor Multiple Potentially Actionable Kinase Fusions

P. Stephens, D. Lipson, V. Miller, 2014 .

Patterns of somatic mutation in human cancer genomes

E. Birney, A. Nicholson, M. Stratton, 2007, Nature.

Extensive High-Depth Sequencing Of Longitudinal CLL Samples Identifies Frequent Mutations In MAP Kinase Signaling and Novel Mutations Activating Notch and Beta-Catenin

A. Zelenetz, P. Stephens, R. Yelensky, 2013 .

Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer

Bin Tean Teh, Chai Yin Kok, Andrew Menzies, 2009, Nature Genetics.

LYMPHOID NEOPLASIA Integrated genomic DNA/RNA pro ﬁ ling of hematologic malignancies in the clinical setting

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016 .

Genomic Profiling of Cancers of Unknown Primary Site--Reply.

P. Stephens, V. Miller, J. Ross, 2015, JAMA oncology.

Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.

J. Lehár, L. Garraway, P. Stephens, 2013 .

General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.

P. Stephens, V. Miller, G. Frampton, 2017, Human pathology.

Comprehensive genomic profiling of malignant phyllodes tumors of the breast

P. Stephens, S. Ganesan, V. Miller, 2017, Breast Cancer Research and Treatment.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Mark Rosenzweig, Joel Greshock, Doron Lipson, 2015, Cancer discovery.

Potentially actionable kinase fusions in inflammatory myofibroblastic tumors.

P. Stephens, D. Lipson, V. Miller, 2013 .

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

P. Stephens, S. Ou, V. Miller, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

James X. Sun, P. Stephens, R. Yelensky, 2014, Clinical Cancer Research.

Cancer gene profile of metastatic breast cancer.

G. Mills, P. Stephens, R. Yelensky, 2012 .

Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.

P. Stephens, R. Yelensky, W. Pao, 2014, Cancer discovery.

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib.

P. Stephens, R. Yelensky, V. Miller, 2016, Journal of the National Cancer Institute.

Comprehensive genomic profiling of sarcomas from 267 adolescents and young adults to reveal a spectrum of targetable genomic alterations.

P. Stephens, V. Miller, L. Davis, 2015 .

Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients

A. Krasnitz, J. Hicks, M. Wigler, 2010, Science Translational Medicine.

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas

Iwei Yeh, Doron Lipson, Thomas Wiesner, 2014, Nature Communications.

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Dara L Aisner, Antonio Jimeno, P. Stephens, 2015, Cancer discovery.

Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies

P. Stephens, R. Yelensky, D. Lipson, 2014, The American journal of surgical pathology.

Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome

P. A. Futreal, P. Stephens, R. Weber, 2011, Clinical Cancer Research.

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer

L. Garraway, P. Stephens, P. Jänne, 2013, Nature Medicine.

Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

P. Stephens, R. Yelensky, D. Lipson, 2016, Clinical Cancer Research.

A survey of homozygous deletions in human cancer genomes.

E. Birney, M. Stratton, P. Futreal, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Sequence analysis of the protein kinase gene family in human testicular germ‐cell tumors of adolescents and adults

Richard Lugg, Andrew Menzies, Keiran Raine, 2006, Genes, chromosomes & cancer.

Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma

P. Stephens, V. Miller, J. Suh, 2017, The American Journal of dermatopathology.

AutoCSA, an algorithm for high throughput DNA sequence variant detection in cancer genomes

Andrew M. Jenkinson, C. Greenman, Rebecca Shepherd, 2007, Bioinform..

Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

James X. Sun, P. Stephens, R. Yelensky, 2013, Clinical Cancer Research.

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

J. Sicklick, P. Stephens, B. Leyland-Jones, 2018, Clinical Cancer Research.

Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia

Peter J. Campbell, Michael R. Stratton, Ben Robinson, 2014, Nature.

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Doron Lipson, Bernard Fendler, Jeffrey P. Gregg, 2018, The Journal of molecular diagnostics : JMD.

Genomic Profiling of Small-Bowel Adenocarcinoma

James X. Sun, P. Stephens, V. Miller, 2017, JAMA oncology.

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Kai Wang, Doron Lipson, Roman Yelensky, 2015, International journal of cancer.

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations

P. Stephens, V. Miller, D. Khaira, 2015, Breast Cancer Research and Treatment.

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy

P. Stephens, R. Yelensky, B. Leyland-Jones, 2015, OncoTargets and therapy.

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.

P. Stephens, V. Miller, Siraj M. Ali, 2017, JCI insight.

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

B. Taylor, P. Stephens, J. Baselga, 2016, Cancer discovery.

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling

P. Stephens, D. Lipson, V. Miller, 2018, Oncotarget.

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.

Trevor J Pugh, James X. Sun, P. Stephens, 2017, Cancer research.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

P. Stephens, R. Yelensky, R. Bose, 2016, Cancer.

Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

J. McPherson, P. Stephens, J. Riess, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy

P. Stephens, V. Miller, Siraj M. Ali, 2019, The Journal of urology.

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.

P. Stephens, T. Choueiri, N. Agarwal, 2018, European urology.

Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy

P. Stephens, G. Chirn, V. Miller, 2017, Cancer.

Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.

P. Stephens, D. Rao, N. Senzer, 2017, Journal of pediatric hematology/oncology.

High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis.

Doron Lipson, James Suh, Jie He, 2017, Cancer research.

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

P. Stephens, T. Ho, T. Choueiri, 2016, European urology focus.

Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.

Zachary J. Heins, N. Schultz, R. Yantiss, 2016, Gastroenterology.

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

David M. Jones, P. Stephens, R. Yelensky, 2014, The oncologist.

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.

P. Stephens, G. Manning, Ayşegül Özen, 2016, Cancer cell.

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

P. Stephens, R. Yelensky, D. Lipson, 2015, The oncologist.

Relapsed classic E-cadherin (CDH1) mutated invasive lobular breast cancer demonstrates a high frequency of HER2 (ERBB2) gene mutations

James X. Sun, P. Stephens, R. Yelensky, 2013 .

Human Cancer Biology Relapsed Classic E-Cadherin ( CDH 1 ) – Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER 2 ( ERBB 2 ) Gene Mutations

James X. Sun, P. Stephens, R. Yelensky, 2013 .

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set

Richard Lugg, Andrew Menzies, Michael R. Stratton, 2006, Molecular Cancer Therapeutics.

Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.

P. Stephens, R. Yelensky, D. Lipson, 2015, The oncologist.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

P. Stephens, R. Yelensky, S. Ou, 2015, The oncologist.

Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation

P. Stephens, D. Beebe, J. Lang, 2016, Clinical Cancer Research.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

M. Rubin, P. Stephens, R. Yelensky, 2013, European urology.

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

James X. Sun, P. Stephens, V. Miller, 2016, Clinical Cancer Research.

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas

P. Stephens, V. Miller, F. Meric-Bernstam, 2017, Oncotarget.

A Small Cell Lung Cancer Genome Reports Complex Tobacco Exposure Signatures Europe Pmc Funders Group

Minna, E. Birney, K. McKernan, 2022 .

Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene

M. Stratton, N. Rahman, P. Stephens, 2009, Journal of Medical Genetics.

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer

P. Stephens, A. Shaw, S. Ou, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

P. Stephens, V. Miller, G. Frampton, 2016, The oncologist.

Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma

P. Stephens, V. Miller, M. Kaag, 2016, Oncotarget.

Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.

P. Stephens, S. Ou, V. Miller, 2015, Lung cancer.

Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

Alex M. Fichtenholtz, P. Stephens, R. Yelensky, 2015 .

Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.

Céline Lefebvre, Jean-Philippe Spano, Frédérique Capron, 2015, European journal of cancer.

RICTOR Amplifi cation Defi nes a Novel Subset of Patients with Lung Cancer Who May Benefi t from Treatment with mTORC 1 / 2 Inhibitors

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

P. Stephens, R. Yelensky, M. Cronin, 2015, BMC Cancer.

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

Kai Wang, Roman Yelensky, Gary Palmer, 2015, JAMA oncology.

Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.

P. Stephens, R. Yelensky, D. Lipson, 2015, Archives of pathology & laboratory medicine.

Identification and characterization of RET fusions in advanced colorectal cancer

P. Stephens, V. Miller, Siraj M. Ali, 2015, Oncotarget.

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses

P. Stephens, R. Yelensky, S. Swisher, 2013, Oncotarget.

Whole exome sequencing of adenoid cystic carcinoma.

M. Stratton, P. Futreal, P. Campbell, 2013, The Journal of clinical investigation.

Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.

P. Stephens, R. Yelensky, E. V. Van Allen, 2016, European urology.

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016, Blood.

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo‐ and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

Vamsidhar Velcheti, Philip J. Stephens, Vincent A. Miller, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.

P. Stephens, V. Miller, N. Ordóñez, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma

P. Stephens, S. Signoretti, A. Hakimi, 2018, British Journal of Cancer.

Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.

P. Stephens, P. Tamboli, E. Jonasch, 2016, European urology.

Evaluation of 122 advanced‐stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies

P. Stephens, R. Yelensky, M. Mihm, 2016, Cancer.

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations

Roland Eils, Rainer König, Rosario M. Piro, 2013, Acta Neuropathologica.

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Kai Wang, Doron Lipson, Roman Yelensky, 2014, Modern Pathology.

Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.

Elisabeth Brambilla, Stéphane Vignot, Roman Yelensky, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

J. Sicklick, P. Stephens, S. Lippman, 2019, Nature Medicine.

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden

Winnie S. Liang, P. Stephens, Y. Oki, 2018, The Oncologist.

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

Philip R. Cohen, P. Stephens, V. Miller, 2017, Oncoimmunology.

Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

M. Stratton, P. Futreal, P. Campbell, 2010, Genes, chromosomes & cancer.

Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.

M. Rubin, P. Stephens, R. Yelensky, 2012, Blood.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC

G. Giaccone, J. Gregg, P. Stephens, 2018, PloS one.

Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

T. Clark, J. Gregg, P. Stephens, 2018, Journal of Hematology & Oncology.

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal

Philip J. Stephens, Doron Lipson, Jean-Charles Soria, 2018, PLoS Comput. Biol..

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

A. Iafrate, P. Stephens, A. Shaw, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3

James X. Sun, P. Stephens, V. Miller, 2018, Cancer.

Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion

P. Stephens, M. Warmuth, P. Zhu, 2017, PloS one.

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.

P. Stephens, S. Ou, V. Miller, 2017, Lung cancer.

Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.

P. Stephens, V. Miller, J. Suh, 2017, The oncologist.

Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.

P. Stephens, S. Ou, V. Miller, 2017, Clinical lung cancer.

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

P. Stephens, V. Miller, G. Frampton, 2017, The oncologist.

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report

P. Stephens, K. Yoneda, G. Frampton, 2017, Journal of Hematology & Oncology.

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias

S. Armstrong, P. Stephens, R. Yelensky, 2016, Leukemia.

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.

P. Stephens, V. Miller, Siraj M. Ali, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion

P. Stephens, V. Miller, F. Meric-Bernstam, 2016, Oncology.

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.

James X. Sun, P. Stephens, V. Miller, 2016, The oncologist.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

Howard Kaufman, Shridar Ganesan, Joseph R. Bertino, 2016, The oncologist.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

P. Stephens, M. Erlander, S. Ou, 2016, Cancer discovery.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Jens Meiler, Taofeek K Owonikoko, Jonathan H Sheehan, 2016, Cancer discovery.

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma

James X. Sun, P. Stephens, R. Yelensky, 2016, Oncology.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

P. Stephens, R. Yelensky, D. Lipson, 2016, Cancer.

Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer

P. Stephens, S. Ou, V. Miller, 2016 .

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Sanjay Goel, Kai Wang, Amit Verma, 2015, Cancer discovery.

Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.

P. Stephens, V. Miller, Siraj M. Ali, 2015, European urology.

Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

P. Stephens, R. Yelensky, Bahar Yilmazel, 2015, Oncoscience.

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening

Joon-Oh Park, P. Stephens, J. Huh, 2015, Oncotarget.

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*

Michael L. Gatza, Alissa M. Weaver, C. Perou, 2015, Molecular & Cellular Proteomics.

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies

P. Stephens, R. Yelensky, D. Lipson, 2014, Journal of Clinical Pathology.

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

P. Stephens, R. Yelensky, D. Lipson, 2014, Journal of Clinical Pathology.

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Peilin Jia, William Pao, Zhongming Zhao, 2014, Cell reports.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

P. Stephens, R. Yelensky, L. Pusztai, 2014, The oncologist.

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

P. Stephens, R. Yelensky, V. Valero, 2016, Oncoscience.

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.

P. Stephens, S. Ou, V. Miller, 2017, Lung cancer.

Abstract 1893: A computational method for somatic versus germline variant status determination from targeted next-generation sequencing of clinical cancer specimens without a matched normal control

James X. Sun, P. Stephens, R. Yelensky, 2014 .

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

P. Stephens, M. Cronin, F. Hirsch, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Case Presentation Alk Fusions Are Also Associated with Younger Age Next-generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib- Sensitive Alk Rearrangement in a Patient with Metastatic Non–small-cell Lung Cancer

P. Stephens, M. Cronin, F. Hirsch, 2012 .

High throughput DNA sequence variant detection by conformation sensitive capillary electrophoresis and automated peak comparison.

M. Stratton, P. Futreal, R. Wooster, 2006, Genomics.

Companion Diagnostics and Cancer Biomarkers Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

G. Mills, P. Stephens, R. Yelensky, 2014 .

Massively Parallel Sequencing Reveals the Complex Structure of an Irradiated Human Chromosome on a Mouse Background in the Tc1 Model of Down Syndrome

Kai Rothkamm, Ruby Banerjee, Fengtang Yang, 2013, PloS one.

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

P. Stephens, R. Yelensky, R. Kurzrock, 2014, Oncotarget.

Abstract A23: Comprehensive next-generation sequencing-based genomic profiling identifies actionable genomic alterations in diverse pediatric tumor types: The Foundation Medicine (FMI) experience

P. Stephens, R. Yelensky, V. Miller, 2014 .

A case of advanced infantile myofibromatosis harboring a novel MYH10‐RET fusion

P. Stephens, M. Rosenzweig, V. Miller, 2017, Pediatric blood & cancer.

Targeted treatment of RAI-resistant metastatic thyroid cancer postcomprehensive genomic profiling.

P. Stephens, S. Ganesan, V. Miller, 2014 .

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Funda Meric-Bernstam, Gordon B Mills, Xiaoping Su, 2014, Molecular Cancer Therapeutics.

Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents

P. Stephens, R. Yelensky, J. Lee, 2014, Molecular Cancer Therapeutics.

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

P. Stephens, R. Yelensky, D. Lipson, 2016, The oncologist.

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.

Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma.

Joaquim M Farinhas, P. Stephens, D. Shin, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Cancer Positive Breast − in Pretreated Advanced Estrogen Receptor Mutations α Emergence of Constitutively Active Estrogen Receptor-Updated

Funda Meric-Bernstam, Rinath Jeselsohn, Lajos Pusztai, 2014 .

Segal and Dowsett , p . 1724 Emergence of Constitutively Active Estrogen Receptor-a Mutations in Pretreated Advanced Estrogen Receptor – Positive Breast Cancer

James X. Sun, P. Stephens, R. Yelensky, 2014 .

Extended Data Figure 5

M. Stratton, P. Campbell, P. Stephens, 2014 .

Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy.

P. Stephens, Runjun D. Kumar, R. Bose, 2017, JCO Precision Oncology.

Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.

P. Stephens, D. Lipson, V. Miller, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies.

J. McPherson, P. Stephens, V. Miller, 2017, JCO Precision Oncology.

Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform

A. Zelenetz, P. Stephens, R. Yelensky, 2013 .

Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2013 .

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Philip J. Stephens, James X. Sun, Garrett M. Frampton, 2016 .

NTRK1 gene fusions as a novel oncogene target in lung cancer.

P. Stephens, P. Jänne, D. Lipson, 2013 .

Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasms

P. Stephens, R. Yelensky, D. Lipson, 2013, Cancer cytopathology.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

J. Sicklick, P. Stephens, S. Lippman, 2019, Nature Medicine.

Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

P. Stephens, S. Ou, V. Miller, 2016, The oncologist.

Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice NEILVASAN, a ROMANYELENSKY, b KAIWANG, b STACYMOULDER, c HANNAHDZIMITROWICZ, a RONIAVRITSCHER, c BALIANGWANG, c

P. Stephens, L. Pusztai, M. Cronin, 2014 .

MA14.01 Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC)

James X. Sun, P. Stephens, S. Ou, 2017 .

Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.

P. Campbell, P. Stephens, N. Munshi, 2009 .

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

P. Stephens, V. Miller, G. Palmer, 2014, Clinical Lymphoma, Myeloma & Leukemia.

Melanoma BRAF Fusions—Response

P. Stephens, W. Pao, J. Sosman, 2014, Clinical Cancer Research.

Comprehensive genomic profiling of parathyroid carcinoma.

P. Stephens, P. Ladenson, V. Miller, 2017 .

Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).

P. Stephens, S. Signoretti, T. Choueiri, 2017 .

Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications.

A. Protopopov, P. Stephens, V. Miller, 2014 .

Patient Derived Xenograft (PDX) Models Faithfully Recapitulate The Genetic Composition Of Primary AML

S. Armstrong, P. Stephens, R. Yelensky, 2013 .

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

P. Stephens, V. Miller, R. Erlich, 2017, Clinical breast cancer.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

James X. Sun, Chang S. Chan, A. Vazquez, 2016, The oncologist.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway.

James X. Sun, P. Stephens, R. Yelensky, 2015 .

Abstract 4699: Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test

M. Ladanyi, P. Stephens, R. Yelensky, 2014 .

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma

P. Stephens, S. Signoretti, T. Choueiri, 2018, British Journal of Cancer.

Abstract LB-178: Genomic profiling of 1239 diverse pediatric cancers identifies novel discoveries across tumors

P. Stephens, D. Lipson, V. Miller, 2016 .

Concordance of driver mutations in primary and matched metastasis from patients with non-small cell lung cancer (NSCLC) using next-generation sequencing (NGS).

P. Stephens, R. Yelensky, M. Cronin, 2012 .

BRAF: An emerging target for triple-negative breast cancer.

P. Stephens, V. Miller, J. Albanell, 2017 .

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Mutations of the BRAF gene in human cancer

A. Nicholson, P. Futreal, R. Wooster, 2002, Nature.

General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.

P. Stephens, V. Miller, G. Frampton, 2017, Human pathology.

Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

P. Stephens, R. Pazdur, A. Al-Hakim, 2013, Clinical Cancer Research.

Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma.

P. Stephens, T. Ho, T. Choueiri, 2016 .

Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.

P. Stephens, V. Miller, N. Ordóñez, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The landscape of cancer genes and mutational processes in breast cancer

A. Børresen-Dale, M. Stratton, M. J. van de Vijver, 2012, Nature.

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.

squamous cell carcinoma identifies novel genetic alterations

P. Stephens, R. Yelensky, C. Boshoff, 2022 .

Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

M. Stratton, P. Futreal, P. Campbell, 2010, Genes, chromosomes & cancer.

Extended Data Table 1

Peter J. Campbell, Michael R. Stratton, Philip J. Stephens, 2014 .